Unfortunately, clinical outcomes after treatment with agents such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have not shown satisfactory improvement due to tumour recurrence and metastasis5. The gene discussed is MTOR; the disease is neoplasm.